Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA7 | P43166 | 2/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15779606 | 1.00 | DGAT1 (0.44) | DGAT1CA1CA7CA12CA14 | |
| SCHEMBL12840763 | 0.83 | ALDH1A1 (0.36) | TDP1 | |
| SCHEMBL15080955 | 0.83 | ALDH1A1 (0.36) | TDP1 | |
| SCHEMBL17801117 | 0.80 | DGAT1 (0.44) | DGAT1CA1CA7TDP1CA2 | |
| SCHEMBL26815955 | 0.80 | DGAT1 (0.44) | DGAT1CA1CA7CA12CA14 | |
| SCHEMBL9064823 | 0.79 | TSHR (0.36) | — | |
| SCHEMBL14485421 | 0.78 | DGAT1 (0.48) | DGAT1CA1CA7CA12CA14 | |
| SCHEMBL12860069 | 0.78 | DGAT1 (0.48) | DGAT1CA1CA7CA12CA14 | |
| SCHEMBL27795979 | 0.78 | DGAT1 (0.43) | DGAT1CA1CA7CA12CA14 | |
| SCHEMBL1115801 | 0.78 | DGAT1 (0.43) | DGAT1CA1CA7CA12CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9751895-B2 | N-[2-(2-amino-6,6-disubstituted-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8H)-yl)-1,3-thiazol-4-yl]amides | PFIZER INC. (US) | 2017-09-05 | — | — | US | disclosed |
| EP-2991989-B1 | IMIDAZO-TRIAZINE DERIVATIVES AS PDE10 INHIBITORS | PFIZER (US) | 2017-06-28 | — | — | EP | disclosed |
| US-9611264-B1 | N-[2-(3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2H-1,2,4-thiadiazin-5-yl)-1,3-thiazol-4-yl] amides | PFIZER INC. (US) | 2017-04-04 | — | — | US | disclosed |
| US-20170088547-A1 | N-[2-(3-AMINO-2,5-DIMETHYL-1,1-DIOXIDO-5,6-DIHYDRO-2H-1,2,4-THIADIAZIN-5-YL)-1,3-THIAZOL-4-YL] AMIDES | PFIZER INC. (US) | 2017-03-30 | — | — | US | disclosed |
| US-20170088558-A1 | N-[2-(2-Amino-6,6-Disubstituted-4,4a,5,6-Tetrahydropyrano[3,4-d][1,3]Thiazin-8a(8H)-YL)-1,3-Thiazol-4-YL]Amides | PFIZER INC. (US) | 2017-03-30 | — | — | US | disclosed |
| WO-2017051294-A1 | N-[2-(3-AMINO-2,5-DIMETHYL-1,1-DIOXIDO-5,6-DIHYDRO-2H-1,2,4-THIADIAZIN-5-YL)-1,3-THIAZOL-4-YL] AMIDES USEFUL AS BACE INHIBITORS | PFIZER INC. (US) | 2017-03-30 | — | — | WO | disclosed |
| WO-2017046675-A1 | NOVEL IMIDAZO [4,5-C] QUINOLINE AND IMIDAZO [4,5-C][1,5] NAPHTHYRIDINE DERIVATIVES AS LRRK2 INHIBITORS | PFIZER INC. (US) | 2017-03-23 | — | — | WO | disclosed |
| US-20170073343-A1 | Novel Imidazo[4,5-c]Quinoline And Imidazo[4,5-c][1,5]Naphthyridine Derivatives As LRRK2 Inhibitors | PFIZER INC. (US) | 2017-03-16 | — | — | US | disclosed |
| US-9527831-B2 | Heteroaromatic compounds and their use as dopamine D1 ligands | PFIZER INC. (US) | 2016-12-27 | — | — | US | disclosed |
| EP-2498746-B1 | SKIN CARE COMPOSITIONS COMPRISING PHENOXYALKYL AMINES | UNILEVER PLC NO 41424 (GB) | 2016-08-24 | — | — | EP | disclosed |
| US-20150005313-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER (US) | 2015-01-01 | — | — | US | disclosed |
| WO-2014207601-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER INC. (US) | 2014-12-31 | — | — | WO | disclosed |
| US-20140343321-A1 | Plasminogen Activator Inhibitor-1 Inhibitors and Methods of Use Thereof to Modulate Lipid Metabolism | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-11-20 | — | — | US | disclosed |
| WO-2014177977-A1 | IMIDAZO-TRIAZINE DERIVATIVES AS PDE10 INHIBITORS | PFIZER INC. (US) | 2014-11-06 | — | — | WO | disclosed |
| US-20140329820-A1 | Triazine Derivatives | PFIZER INC. (US) | 2014-11-06 | — | — | US | disclosed |
| EP-2594651-A1 | Analysis of methylation sites | Vilnius University (LT) | 2013-05-22 | — | — | EP | disclosed |
| US-20120237598-A1 | ANTI-CONSTIPATION COMPOSITION | SUCAMPO AG (CH) | 2012-09-20 | — | — | US | disclosed |
| US-8114890-B1 | Anti-constipation composition | SUCAMPO AG (CH) | 2012-02-14 | — | — | US | disclosed |
| US-20120022152-A1 | ANTI-CONSTIPATION COMPOSITION | SUCAMPO AG (CH) | 2012-01-26 | — | — | US | disclosed |
| US-7417067-B2 | Composition and method for stabilizing the same | SUCAMPO AG (CH) | 2008-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170073343-A1 | Novel Imidazo[4,5-c]Quinoline And Imidazo[4,5-c][1,5]Naphthyridine Derivatives As LRRK2 Inhibitors | LRRK2, PARK7, SNCA | DGAT1 4614/4885CA1 4820/4885CA7 4777/4885 |
| US-20140329820-A1 | Triazine Derivatives | PDE12, PDE5A, PDE10A | DGAT1 3424/4885CA1 3674/4885CA7 904/4885 |
| US-20170088547-A1 | N-[2-(3-AMINO-2,5-DIMETHYL-1,1-DIOXIDO-5,6-DIHYDRO-2H-1,2,4-THIADIAZIN-5-YL)-1,3-THIAZOL-4-YL] AMIDES | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TBXA2R, TH | DGAT1 3238/4885CA1 3043/4885CA7 3246/4885 |
| US-20140343321-A1 | Plasminogen Activator Inhibitor-1 Inhibitors and Methods of Use Thereof to Modulate Lipid Metabolism | SERPINE1, PLAT, SERPINB1 | DGAT1 166/4885CA1 3712/4885CA7 3953/4885 |
| US-20170088558-A1 | N-[2-(2-Amino-6,6-Disubstituted-4,4a,5,6-Tetrahydropyrano[3,4-d][1,3]Thiazin-8a(8H)-YL)-1,3-Thiazol-4-YL]Amides | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, UGT1A8, TBXA2R | DGAT1 4359/4885CA1 2438/4885CA7 1718/4885 |
| US-20150005313-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | SNCA, DRD1, DRD2 | DGAT1 1119/4885CA1 3197/4885CA7 4495/4885 |
| US-20120022152-A1 | ANTI-CONSTIPATION COMPOSITION | SLC10A2, FABP6, VIP | DGAT1 1466/4885CA1 422/4885CA7 176/4885 |
| US-20120237598-A1 | ANTI-CONSTIPATION COMPOSITION | SLC10A2, FABP6, VIP | DGAT1 1466/4885CA1 422/4885CA7 176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.